Pivotal Point Follow-up Kodiak Sciences (KOD): Strong Phase 3 Study Data in Ophthalmology Triggers a Massive Price Surge

Kodiak Sciences is a US biopharma company that develops novel therapies for the treatment of severe retinal diseases. On September 28, the company announced the successful completion of the pivotal Phase 3 study DAYBREAK for the active substances Zenkuda and KSI-501 for the treatment of wet age-related macular degeneration. Both medications achieved the primary endpoint and demonstrated their efficacy compared to the established standard drug Eylea. The company is now preparing the regulatory submissions to the US Food and Drug Administration (FDA)...